2 days Ago By ABMN Staff
Annovis Bio ( NYSE:ANVS – Get Free Report ) and Eterna Therapeutics ( NASDAQ:ERNA – Get Free Report ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Risk & Volatility Annovis Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Comparatively, Eterna Therapeutics has a beta of 4.79, indicating that its share price is 379% more volatile than the S&P 500. Insider & Institutional Ownership 15.
8% of Annovis Bio shares are owned by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are owned by institutional investors.
32.3% of Annovis Bio shares are owned by company insiders. Comparatively, 4.
5% of Eterna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Profitability Analyst Ratings This is a breakdown of current recommendations and price targets for Annovis Bio and Eterna Therapeutics, as provided by MarketBeat.
com. Annovis Bio presently has a consensus target price of $37.00, indicating a potential upside of 2,848.
21%. Given Annovis Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Annovis Bio is more favorable than Eterna Therapeutics. Earnings and Valuation This table compares Annovis Bio and Eterna Therapeutics”s revenue, earnings per share and valuation.
Eterna Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks. Summary Annovis Bio beats Eterna Therapeutics on 7 of the 13 factors compared between the two stocks.
About Annovis Bio ( Get Free Report ) Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania. About Eterna Therapeutics ( Get Free Report ) Eterna Therapeutics Inc.
, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.
com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
